Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A | Experimental |
| |
| Sequence B | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DA-2902 | Drug | single dose administration (DA-2902 one tablet once a day) |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUCt | pre-dose ~ 72 hr of pose-dose | |
| Cmax | pre-dose ~ 72 hr of post-dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHA University Bundang Medical Center | Seongnam-si | Gyeonggi-do | 13520 | South Korea |
Not provided
| ID | Term |
|---|---|
| D003141 | Communicable Diseases |
| ID | Term |
|---|---|
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DA-2902-R | Drug | single dose administration (DA-2902-R one tablet once a day) |
|